{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:09:14Z","timestamp":1785150554631,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100003181","name":"National Niemann-Pick Disease Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003181","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Niemann-Pick UK"},{"name":"International Niemann-Pick Disease Alliance"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acid Sphingomyelinase Deficiency (ASMD) is an ultra-rare autosomal recessive lysosomal storage disorder characterized by intracellular lipid accumulation resulting from reduced function of acid sphingomyelinase. Olipudase alfa, an enzyme replacement therapy, was recently approved in several countries for the treatment of the non-neurologic manifestations of ASMD. Studies demonstrate improvement in organomegaly, pulmonary function and lipid profiles with olipudase alfa, yet little is known about its impact on quality of life (QoL) for patients and caregivers. The purpose of this study is to better understand the real-life impact of ASMD on patients and caregivers and assess how olipudase alfa impacts QoL for pediatric patients and their caregivers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Caregivers of pediatric patients (\u2264\u200918\u00a0years of age) with a confirmed diagnosis of ASMD that received olipudase alfa for at least 12\u00a0months were recruited in early 2022 through national patient organizations to participate in a global online questionnaire followed by semi-structured interviews. Ten caregivers of patients with ASMD who utilized olipudase alfa as an experimental therapy for pediatric patients participated in the study. Quantitative analysis of the results was undertaken, and qualitative data was analyzed using an inductive thematic approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten eligible participants completed questionnaires, and 8 of the 10 went on to participate in structured interviews. Symptom burden of ASMD and impact on symptomatology and quality of life after olipudase alfa use are reported here. Five themes emerged from analysis: (1) ASMD is a systemic disease with a wide array of manifestations that significantly impact QoL; (2) Olipudase alfa was associated with improvements in all non-neurologic manifestations of ASMD; (3) Participants perceived the risk associated with olipudase alfa to be low and the benefits to greatly outweigh any risk or burden; (4) Participants reported an unmet need to treat the neurologic manifestations of the disease despite the benefits of olipudase alfa in the management of non-neurological symptoms; (5) Participants felt all patients with ASMD need access to olipudase alfa based on the life-changing experience they perceived.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings highlight the sustained positive impact olipudase alfa had in many domains that are deemed important to patients and families living with ASMD and outline the extensive unmet need for patients and families living with ASMD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-024-03020-4","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T12:02:37Z","timestamp":1706788957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-life impacts of olipudase alfa: The experience of patients and families taking an enzyme replacement therapy for acid sphingomyelinase deficiency"],"prefix":"10.1186","volume":"19","author":[{"given":"Eva M.","family":"Raebel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6732-5374","authenticated-orcid":false,"given":"Conan","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Mathieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson","family":"Pountney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joslyn","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hopkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"3020_CR1","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s10545-007-0632-9","volume":"30","author":"EH Schuchman","year":"2007","unstructured":"Schuchman EH. The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann\u2013Pick disease. J Inherit Metab Dis. 2007;30:654\u201363. https:\/\/doi.org\/10.1007\/s10545-007-0632-9.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"3020_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.beem.2014.10.002","volume":"29","author":"EH Schuchman","year":"2015","unstructured":"Schuchman EH, Wasserstein MP. Types A and B Niemann\u2013Pick disease. Best Pract Res Clin Endocrinol Metab. 2015;29(2):237\u201347. https:\/\/doi.org\/10.1016\/j.beem.2014.10.002.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"3020_CR3","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ymgme.2016.05.001","volume":"118","author":"D Cassiman","year":"2016","unstructured":"Cassiman D, Packman S, Bembi B, Turkia HB, Al-Sayed M, Schiff M, Imrie J, Mabe P, Takahashi T, Mengel KE, Giugliani R. Cause of death in patients with chronic visceral and chronic neurovisceral acid sphingomyelinase deficiency (Niemann\u2013Pick disease type B and B variant): literature review and report of new cases. Mol Genet Metab. 2016;118(3):206\u201313. https:\/\/doi.org\/10.1016\/j.ymgme.2016.05.001.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"3020_CR4","doi-asserted-by":"publisher","first-page":"e672","DOI":"10.1542\/peds.2004-0887","volume":"114","author":"MP Wasserstein","year":"2004","unstructured":"Wasserstein MP, Desnick RJ, Schuchman EH, Hossain S, Wallenstein S, Lamm C, McGovern MM. The natural history of type B Niemann\u2013Pick disease: results from a 10-year longitudinal study. Pediatrics. 2004;114(6):e672\u20137. https:\/\/doi.org\/10.1542\/peds.2004-0887.","journal-title":"Pediatrics"},{"issue":"4","key":"3020_CR5","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.jpeds.2006.06.034","volume":"149","author":"MP Wasserstein","year":"2006","unstructured":"Wasserstein MP, Aron A, Brodie SE, Simonaro C, Desnick RJ, McGovern MM. Acid sphingomyelinase deficiency: prevalence and characterization of an intermediate phenotype of Niemann\u2013Pick disease. J Pediatr. 2006;149(4):554\u20139. https:\/\/doi.org\/10.1016\/j.jpeds.2006.06.034.","journal-title":"J Pediatr"},{"issue":"2","key":"3020_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1212\/01.wnl.0000194208.08904.0c","volume":"66","author":"MM McGovern","year":"2006","unstructured":"McGovern MM, Aron A, Brodie SE, Desnick RJ, Wasserstein MP. Natural history of Type A Niemann\u2013Pick disease: possible endpoints for therapeutic trials. Neurology. 2006;66(2):228\u201332. https:\/\/doi.org\/10.1212\/01.wnl.0000194208.08904.0c.","journal-title":"Neurology"},{"issue":"1","key":"3020_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13023-017-0572-x","volume":"12","author":"MM McGovern","year":"2017","unstructured":"McGovern MM, Avetisyan R, Sanson BJ, Lidove O. Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD). Orphanet J Rare Dis. 2017;12(1):41. https:\/\/doi.org\/10.1186\/s13023-017-0572-x.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"3020_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.beem.2014.08.004","volume":"29","author":"SD Kingma","year":"2015","unstructured":"Kingma SD, Bodamer OA, Wijburg FA. Epidemiology and diagnosis of lysosomal storage disorders; challenges of screening. Best Pract Res Clin Endocrinol Metab. 2015;29(2):145\u201357. https:\/\/doi.org\/10.1016\/j.beem.2014.08.004.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"3020_CR9","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1186\/s13023-017-0572-x","volume":"122","author":"MM McGovern","year":"2008","unstructured":"McGovern MM, Wasserstein MP, Giugliani R, Bembi B, Vanier MT, Mengel E, Brodie SE, Mendelson D, Skloot G, Desnick RJ, Kuriyama N, Cox GF. A prospective, cross-sectional survey study of the natural history of Niemann\u2013Pick disease type B. Pediatrics. 2008;122(2):e341\u20139. https:\/\/doi.org\/10.1186\/s13023-017-0572-x.","journal-title":"Pediatrics"},{"issue":"193","key":"3020_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-022-02335-4","volume":"17","author":"S Hassall","year":"2022","unstructured":"Hassall S, Smith DM, Rust S, Jones SA, Wittkowski A. \u201cWhy them, why me, why us?\u201d The experiences of parents of children with lysosomal acid lipase deficiency: an interpretative phenomenological analysis study. Orphanet J Rare Dis. 2022;17(193):1\u201311. https:\/\/doi.org\/10.1186\/s13023-022-02335-4.","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"3020_CR11","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41436-021-01156-3","volume":"23","author":"GA Diaz","year":"2021","unstructured":"Diaz GA, Jones SA, Scarpa M, Mengel KE, Giugliani R, Guffon N, et al. One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency. Genet Med. 2021;23(8):1543\u201350. https:\/\/doi.org\/10.1038\/s41436-021-01156-3.","journal-title":"Genet Med"},{"key":"3020_CR12","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.gim.2022.03.021","volume":"24","author":"M Wasserstein","year":"2022","unstructured":"Wasserstein M, Lachmann R, Hollak C, Arash-Kaps L, Barbato A, Gallagher RC, Giugliani R, Guelbert NB, Ikezoe T, Lidove O, Mabe P, Mengel E, Scarpa M, Senates E, Tchan M, Villarrubia J, Chen Y, Furey S, Thurberg BL, Zaher A, Kumar M. A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results. Genet Med. 2022;24:1425\u201336. https:\/\/doi.org\/10.1016\/j.gim.2022.03.021.","journal-title":"Genet Med"},{"key":"3020_CR13","unstructured":"Company Name: Qualtrics, Development Company: Qualtrics, First release: 2005, Copyright Year: 2022. Location: Provo, Utah, USA, Version: Feb 2022, Available at: https:\/\/www.qualtrics.com"},{"issue":"4","key":"3020_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/2159676X.2019.1628806","volume":"11","author":"V Braun","year":"2019","unstructured":"Braun V, Clarke V. Reflecting on reflexive thematic analysis. Qual Res Sport Exerc Health. 2019;11(4):589\u201397. https:\/\/doi.org\/10.1080\/2159676X.2019.1628806.","journal-title":"Qual Res Sport Exerc Health"},{"issue":"9","key":"3020_CR15","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","volume":"89","author":"BC Obrien","year":"2014","unstructured":"Obrien BC, Harris IB, Beckman TJ, et al. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245\u201351. https:\/\/doi.org\/10.1097\/ACM.0000000000000388.","journal-title":"Acad Med"},{"key":"3020_CR16","doi-asserted-by":"publisher","first-page":"20972","DOI":"10.1038\/S41598-021-99921-6","volume":"11","author":"R Pokrzywinski","year":"2021","unstructured":"Pokrzywinski R, Hareendran A, Nalysnyk L, Cowie S, Crowe J, Hopkin J, Joshi D, Pulikottil-Jacob R. Impact and burden of acid sphingomyelinase deficiency from a patient and caregiver perspective. Sci Rep. 2021;11:20972. https:\/\/doi.org\/10.1038\/S41598-021-99921-6.","journal-title":"Sci Rep"},{"key":"3020_CR17","doi-asserted-by":"publisher","first-page":"S208","DOI":"10.1016\/j.jval.2021.04.1044","volume":"24","author":"C Mansfield","year":"2021","unstructured":"Mansfield C, Nalysnyk L, Joshi D, Coulter J, Pulikottil-Jacob R. Patient and parent preferences for symptom control in ASMD Type B and A\/B using best-worse scaling methodology. Value Health. 2021;24:S208. https:\/\/doi.org\/10.1016\/j.jval.2021.04.1044.","journal-title":"Value Health."},{"issue":"3","key":"3020_CR18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/jimd.12482","volume":"45","author":"S Hassall","year":"2022","unstructured":"Hassall S, Smith DM, Rust S, Wittkowski A. A systematic review and integrative sequential explanatory narrative synthesis: the psychosocial impact of parenting a child with a lysosomal storage disorder. J Inherit Metab Dis. 2022;45(3):406\u201316. https:\/\/doi.org\/10.1002\/jimd.12482.","journal-title":"J Inherit Metab Dis"},{"key":"3020_CR19","doi-asserted-by":"publisher","first-page":"559804","DOI":"10.3389\/fmolb.2020.559804","volume":"7","author":"MJ Edelmann","year":"2020","unstructured":"Edelmann MJ, Maegawa GH. CNS-targeting therapies for lysosomal storage diseases: current advances and challenges. Front Mol Biosci. 2020;7:559804. https:\/\/doi.org\/10.3389\/fmolb.2020.559804.","journal-title":"Front Mol Biosci"},{"issue":"11","key":"3020_CR20","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1002\/ajmg.a.33077","volume":"149","author":"SL Henderson","year":"2009","unstructured":"Henderson SL, Packman W, Packman S. Psychosocial aspects of patients with Niemann-pick disease, type B. Am J Med Genet A. 2009;149(11):2430\u20136. https:\/\/doi.org\/10.1002\/ajmg.a.33077.","journal-title":"Am J Med Genet A"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03020-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03020-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03020-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T12:06:15Z","timestamp":1706789175000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03020-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3020"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03020-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2513585\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]},"assertion":[{"value":"26 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted in accordance with the British Healthcare Business Intelligence Association\u2019s Legal and Ethical Guidelines for Market Research. Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}